Methicillin-resistant Staphylococcus aureus

Staphylococcus aureus

Bacteria

Biology

Genetics

Antibiotics

Microbiology

Medicine

Vancomycin

Enterococcus

Journal of Advanced Research

The infection caused by methicillin-resistant Staphylococcus aureus (MRSA) is a global threat to public health. Vancomycin remains one of the first-line drugs for the treatment of MRSA infections. However, S. aureus isolates with complete resistance to vancomycin have emerged in recent years. Vancomycin-resistant S. aureus (VRSA) is mediated by a vanA gene cluster, which is transferred from vancomycin-resistant enterococcus. Since the first VRSA isolate was recovered from Michigan, USA in 2002, 52 VRSA strains have been isolated worldwide. In this paper, we review the latest progresses in VRSA, highlighting its resistance mechanism, characteristics of VRSA infections, as well as clinical treatments.

Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features